Table 1.

Antipsychotic Medication Side Effects^*

Class	Generic Name	Trade Name	Metabolic abnormalities‡	EPS/TD§	Hyperprolactinemia
Second Generation Antipsychotics	Aripiprazole	Abilify	+	++	+
	Asenapine	Saphris	Unknown	Unknown	Unknown
	Clozapine	Clozaril	++++	+	+
	Iloperidone	Fanapt	Unknown	Unknown	Unknown
	Lurasidone	Latuda	Unknown	Unknown	Unknown
	Olanzapine†	Zyprexa	++++	++	++
	Paliperidone†	Invega	+++	+++	++++
	Quetiapine†	Seroquel	+++	+	+
	Risperidone†	Risperdal	+++	+++	++++
	Ziprasidone	Geodon	+	++	++
Commonly Used First Generation Antipsychotics	Chlorpromazine	Thorazine	++++	++	+++
	Fluphenazine†	Prolixin	++	++++	++++
	Haloperidol†	Haldol	++	++++	++++
	Perphenazine	Trilafon	+++	+++	+++

+ = minimal risk ++ = low risk +++ = moderate risk ++++ = high risk

† Long-acting injectables are assumed to have the same side effect profile as the oral preparations. However, some advantages for long-acting preparations due to more uniform serum concentrations may be possible

‡Given the significant overlap in risk, weight gain, lipid abnormalities, and diabetes were combined into one category

§ EPS = Extrapyramidal symptoms; TD = tardive dyskinesia

Sources: The primary source for all ratings is The 2009 Schizophrenia PORT Psychopharmacologic Treatment Recommendations and Summary Statements (Buchanan 2009). Since no single source covers all of the side effects for all drugs, additional sources for specific side effects include: Weight/metabolic (Newcomer 2005, Allison 1999, Nasrallah 2009), EPS/TD (Sadock 2007, Miyamoto 2008, Nasrallah 2009), and Hyperprolactinemia (Bushe 2008). Expert consultation was used when sources conflicted

* Adapted with permission from Dr. LloydSederer⁴⁰